Chronic kidney disease (CKD), a condition in which the kidneys are unable to clear waste products, affects 700 million people globally. Genome-wide association studies (GWASs) have identified sequence variants for CKD; however, the biological basis of these GWAS results remains poorly understood. To address this issue, we created an expression quantitative trait loci (eQTL) atlas for the glomerular and tubular compartments of the human kidney. Through integrating the CKD GWAS with eQTL, single-cell RNA sequencing and regulatory region maps, we identified novel genes for CKD. Putative causal genes were enriched for proximal tubule expression and endolysosomal function, where DAB2, an adaptor protein in the TGF-β pathway, formed a central node. Functional experiments confirmed that reducing Dab2 expression in renal tubules protected mice from CKD. In conclusion, compartment-specific eQTL analysis is an important avenue for the identification of novel genes and cellular pathways involved in CKD development and thus potential new opportunities for its treatment.
C KD affects close to 10% of the population worldwide 1, 2 . Despite advances in therapeutic methods such as dialysis and transplantation, CKD remains the ninth leading cause of death in the world 3, 4 . The precise molecular and cellular mechanisms underlying CKD pathogenesis are still poorly understood 5 . As a result, current treatments are mostly palliative rather than truly curative.
It is estimated that 20% of individuals with CKD in the United States harbor potentially identifiable and causal (for CKD) mutations in a single gene 6, 7 . The majority of individuals with CKD exhibit a polygenic architecture with an estimated heritability proportion of around 30-50% (ref. 8 ). Large-scale GWASs using more than 100,000 subjects were performed to unravel the genetics of kidney function and CKD in the general population, and these successfully identified a total of 53 loci significantly associated with kidney disease 9 . Currently, there are 83 loci that have a genomewide significant association with kidney disease traits [9] [10] [11] [12] . As seen for traits associated with other diseases or other conditions, more than 95% of variants significantly associated with kidney function are in the noncoding regions of the genome 13, 14 .
GWASs often label risk-allele regions by their proximity to specific genes. However, regulatory elements can act over large distances and in a cell-type-specific manner, making the identification of disease-causing genes and their mechanism exceedingly difficult 15, 16 . For example, specific genes that explain the common genetic variation associated with hyperlipidemia, diabetes and heart disease have been uncovered only for a handful of loci [17] [18] [19] . These studies support a model in which causal nucleotide variants are localized to cell-type-specific regulatory regions, such as enhancers, that alter transcription factor binding and induce quantitative differences in transcript levels of nearby causal genes 20, 21 . One such example is the fat mass and obesity-associated (FTO) gene region; variants in the intronic region of FTO show strong association with obesity, but the actual causal genetic variation was an enhancer modulating the expression of the transcription factors IRX3 and IRX5, which are encoded near the FTO gene 22 . These observations highlight the critical importance of careful, unbiased, in-depth follow-up studies to GWASs to better confirm or identify the actual causal genes for a given pathological condition.
Several large collaborative efforts have been set up to better understand complex trait variations. The Encyclopedia of DNA Elements (ENCODE) project is an important international effort to identify regulatory regions that could harbor disease-causing variants. The project has generated regulatory region maps for a large number of cell types and organs 23, 24 . Similarly, the Genotype-Tissue Expression (GTEx) project provided one of the largest and most comprehensive catalogs of whole-genome and transcriptome sequencing data, comprising up to 53 human tissue samples across 635 individuals defining an association between genetic variant and gene expression; this was also called eQTL analysis [25] [26] [27] . Nonetheless, the human kidney has been poorly covered both by ENCODE 28, 29 and GTEx [25] [26] [27] studies. To address this issue, our group has previously generated histone chromatin immunoprecipitation sequencing (ChIP-seq) data to annotate kidney-specific regulatory regions and performed eQTL analyses on 96 human whole-kidney tissue samples 30 . As a result of this whole-tissue-based analysis, we identified putative disease-associated genes for 5 of the 83 previously identified CKD-associated loci identified through GWAS. Candidate gene and animal model studies indicated that UMOD and SHROOM3 are the likely causal genes for CKD GWAS variants. 31, 32 . Causal genes and pathways for the remaining 76 loci remain unknown to date.
Here we argue that the cell-type heterogeneity of the eQTL dataset and the sample size limitation are the key contributors to the low yield of identified causal genes for CKD using the GWAS-eQTL integration approach 24, [33] [34] [35] . Our recent single-cell transcriptome analysis highlighted important cell-type convergence, indicating that diseases that present with similar phenotypes originate from the same cell types 36 . We propose that diseases are not organ-specific but rather are cell-type-specific; therefore, genetic variants are localized to cell-type-specific regulatory regions and influence gene expression changes only in disease-causing cell types 35, 37, 38 .
As a first step toward identifying CKD-associated genes, we performed a compartment-based eQTL analysis of human kidney tissue samples using manual microdissection of the glomerulus and tubule, which are two key compartments of this organ. This microdissection markedly reduces cell heterogeneity, as each compartment is composed of around only five cell types 36 . We aimed to define genotype-driven gene expression changes in the glomerular and tubular compartments of human kidneys, identifying genetic variants that influence the expression of genes. Here, we call genetic variants that influence gene expression eVariants and their target genes eGenes.
Subsequently, we integrated this information with genotype and phenotype association studies (that is, GWAS hits) to identify genes which are differentially expressed between the kidneys of individuals with different alleles of GWAS-identified variants ( Supplementary Fig. 1a ). We show that compartment-based eQTL data markedly improves identification of genes for which expression is regulated by GWAS-identified variants. Furthermore, we integrated the kidney eQTL data with epigenomic data and transcriptome analysis from single-cell RNA sequencing (RNA-seq) to study the regulatory mechanism of the cell-type-specific eQTL effects of disease-causing genetic variants. Finally, we performed cell-type-specific gene expression manipulations in animal models and specifically demonstrated that DAB2 is likely a causal gene for CKD development. Our study provides a new genetic framework for CKD development, as it defines key cell types and new mechanisms involved in the disease.
Results
Compartment-based eQTLs in the human kidney. We separated human kidney tissue compartments, in particular glomeruli and tubules, by manual microdissection; this was followed by RNAseq of each compartment ( Supplementary Fig. 1b ). The expression of tubule-epithelial-specific markers, such as SLC12A1 and SLC34A1, was significantly greater in tubules (P < 2.2 × 10 −16 and P = 3.59 × 10 −11 , respectively; two-sided Student's t-test), whereas glomerulus-epithelial-specific genes were almost exclusively expressed in glomeruli ( Supplementary Fig. 1c ). Well-known genes associated with nephrotic syndrome showed preferential expression in the glomerular compartment, and proximal tubulopathy genes were expressed in tubules ( Supplementary Fig. 1d ). We validated that the fraction of each cell type was similar in the kidney samples included in the analysis using in silico cell deconvolution analysis that estimates cell-type proportions on the basis of latent variable modeling 39, 40 ( Supplementary Fig. 1e ). Furthermore, tissue samples underwent careful clinical and histological evaluation, and we included samples only without obvious structural and functional changes in the analysis to minimize nongenetically-driven fluctuations in gene expression (Supplementary Table 1 ).
Using these stringent criteria, we selected 151 kidneys for the analysis, including 121 tubule samples and 119 glomerulus samples used to identify compartment-based cis-eQTLs (further referred to as eQTLs) ( Supplementary Fig. 1f ). We performed eQTL analysis separately for the two compartments by using a linear model and a ± 1-Mb window around the transcription start site (TSS). In the tubular compartment, we identified 4,081 genes with eQTLs at a 5% false discovery rate (FDR) (hereafter referred to as eGenes) and 389,454 significant SNP-gene pairs; in the glomerular compartment, we identified 4,913 eGenes and 467,994 significant SNP-gene pairs. We made this dataset available via our searchable website (http://susztaklab.com/eqtl/). We also performed meta-analysis on tubules and glomeruli eQTLs and defined tubule-compartment-specific eGenes (n = 417), glomerulus-compartment-specific eGenes (n = 674) and compartmentshared eGenes (n = 3,493) ( Fig. 1a ).
The number of eGenes identified is in line with expectations ( Supplementary Fig. 2a ) from previous publications examining 44 human tissues in the GTEx Consortium 25 . Furthermore, many of the significant SNP-gene pairs identified by our tubule eQTL analysis can be replicated in other tissues (thyroid (π 1 = 0.79) and transformed fibroblasts cells (π 1 = 0.77); π 1 refers to the proportion of true positives). As expected, the greatest overlap for tubule was observed in glomeruli (π 1 = 0.91) ( Supplementary Fig. 2b ).
By performing meta-analysis of kidney compartments and 44 GTEx tissue samples, we could identify 589 tubule-specific eGenes (m > 0.9 in less than five tissues, including tubule; m refers to the posterior probability that the effect is shared in each tissue) and 594 glomerulus-specific eGenes. We found 7,050 shared eGenes in the tubules (m > 0.9 in more than 40 tissues, including tubule) and 7,090 shared eGenes in the glomerulus. These results are in line with previous observations indicating that most eGenes were shared across tissues 25 (Fig. 1b) .
Our compartment-based eQTL study identified many new eQTLs that were previously not detected by bulk-tissue, whole-kidney eQTL analysis (Supplementary Table 2 ). For example, LRRC3 is associated with the rs2838917 genotype only in the tubular compartment, but not in whole kidney or the glomerulus ( Supplementary  Fig. 2c,d ). In contrast, ANXA2 is associated with the rs3068 genotype only in the glomerular compartment ( Supplementary Fig. 2e ,f). Of note, we found that one gene, NUCB1, has an opposite eQTL effect direction between tubule and glomerulus ( Supplementary Fig. 2g) . These examples highlight the utility of compartment-based eQTL analysis to identify a large number of new eQTLs.
Renal compartment eQTLs are enriched for kidney-associated GWAS trait variants. By assessing overlap between the entire published GWAS catalog 41 (downloaded 4 January 2017) and our kidney compartment eQTLs, we found that GWAS hits in genes encoding proteins that are related to regulating the levels various blood metabolites were significantly enriched for tubule eQTLs. Of the metabolite GWAS hits, 26% colocalized with tubule eQTLs, and its associated genes were significantly enriched for tubule eGenes (P = 3.04 × 10 −6 , Fisher's exact test). Moreover, tubule eGenes were also significantly enriched for genes associated with kidney disease traits, such as IgA nephropathy (P = 2.12 × 10 −3 ). A similar pattern of kidney and metabolite trait enrichment was seen in the glomerulus eQTL dataset ( Fig. 1c ).
Next, we focused on our newly identified tubule-specific and glomerulus-specific eGenes by assessing overlap with the GWAS catalog. Tubule-specific eGenes, compared to nontubule-specific eGenes, were significantly enriched for CKD GWAS hits (P = 4.79 × 10 −3 , Fisher's exact test) and glomerular filtration rate GWAS hits (P = 7.96 × 10 −3 ). In contrast, these tubule-shared eGenes were enriched in genes for inflammatory skin disease (P = 5.94 × 10 −3 ) and Parkinson's disease (P = 2.95 × 10 −2 ) compared with nontubule-shared eGenes. Glomerulus-specific eGenes were not only enriched for CKD GWAS variants but also for blood pressure-associated genetic variants (Fig. 1d ). In summary, these results a indicate that kidney-specific eQTLs show enrichment for kidneyassociated phenotypic traits, but shared eQTLs showed no enrichment for renal traits, thus confirming the specificity and biological relevance of compartment-based eQTL analysis.
Integration of CKD GWAS variants and compartment-based eQTLs to identify causal genes for kidney disease.
Our goal was to annotate CKD-associated GWAS variants to identify genes and pathways responsible for CKD development. Through a literature survey, we identified a total of 83 replicated, CKD-associated GWAS loci [9] [10] [11] [12] (Supplementary Table 3 ). A direct overlap of loci that reached genome-wide significance in GWAS for CKD and in our eQTL data identified differences in the expression level of 27 genes associated with CKD GWAS loci. To test whether two traits share a causal variant at a given locus, we conducted colocalization analysis using coloc 42 . And, in a complementary analysis to assess whether a GWAS SNP tags the same functional variant as the eQTL, we calculated regulatory trait concordance (RTC) scores 43 for each candidate SNP-gene pair. Most of these genetic regions showed a positive colocalization between the eQTL effect and CKD GWAS (posterior probability of colocalization between eQTL and GWAS effect in the given region (PP_H4) > 0.8), suggesting that these genes are strong causal candidates for kidney disease ( Table 1 ). The functional role of MANBA, PGAP3 and CASP9 for kidney disease development has been supported by prior animal model studies, confirming the biological validity of our computational analysis 44, 45 .
In summary, when compared to previous eQTL studies of wholekidney tissue samples, the compartment-based eQTL analysis could identify a larger number of causal genes for CKD (n = 5 for bulk tissue and n = 27 for specific compartment). Furthermore, despite the significant eQTL sharing (π 1 = 0.91) between tubule and glomerulus, more causal genes identified in GWAS came from the smaller, newly discovered, compartment-specific eQTL subset.
Compartment-specific eQTLs are enriched in distal regulatory regions and show greater cell-type specificity.
We hypothesized that integration of GWAS with compartment eQTLs can identify potential causal cell types for a given set of traits ( Fig. 2a ). To further understand whether the 27 genes with GWAS overlapping compartment-based eQTLs show cell-type specificity, we have examined the expression of putative GWAS target genes in kidney cells. We have previously performed single-cell RNA-seq on mouse kidney tissue samples, and our analysis has identified 16 distinct cell types in the kidney 36 . Using this unique expression dataset (only 13 wellannotated cell types), we next examined the cell types for which putative GWAS target genes are expressed. We were able to map the expression of 23 out of the 27 human target genes in our mouse kidney single-cell atlas. We found that most CKD-associated genes have a unique cell-type-enriched expression profile and that these transcripts are not broadly expressed in all kidney cells. Particularly, we found that renal proximal tubules show the greatest enrichment for GWAS-eQTL target genes, where 39% of genes (9 out of 23) are expressed in proximal tubule epithelial cells, which is markedly higher than what is expected if genes were randomly distributed in kidney cells (23 genes, 13 cell types; ~1 gene per cell type) ( Fig. 2b) .
In our analysis, as observed by GTEx and most prior studies, the identified eQTLs were mostly enriched on promoters ( Supplementary Fig. 3a ). Upon examining for binding sites of transcription factors, we found enrichment for genes encoding SAP30, KDM5A, HDAC1, CREB1, ELK4 and ESRRA, key transcription factors that are proposed to be involved in maintaining the high metabolic rate of proximal tubule cells ( Supplementary Fig. 3b ).
We reasoned that if compartment-based eQTLs are more informative for GWAS annotation, then compartment-specific eGenes must arise from variants that are localized to cell-type-specific regulatory regions, such as distant regulatory regions (e.g., enhancers), rather than proximal regulatory regions (i.e., promoters) that are mostly shared between cell types. When we compared shared and compartment-specific eGenes, we found that their eQTL variants were significantly further away from the TSS for compartment-specific eGenes compared to shared eGenes, indicating that compartment-specific eQTLs might be linked to more distal (i.e., enhancer) regulatory variants ( Fig. 2c,d) .
To further investigate this finding, we compared the genomic feature annotations for compartment-specific eGenes and compartment-shared eGenes using ChIP-seq data derived from adult human kidney. Compartment-shared eGenes were significantly more enriched in promoters than compartment-specific eGenes (P < 2.2 × 10 −16 , Wilcoxon rank-sum test) ( Fig. 2e ). Moreover, we examined whether cell-type-specific enrichment would explain the identification of compartment-specific eGenes. We found that glomerulus-compartment-specific eGenes were significantly enriched for expression in podocytes (P = 2.91 × 10 −7 , Fisher's exact test), and tubule-compartment-specific eGenes were enriched for expression in tubule epithelial cells (P = 6.14 × 10 −2 , Fisher's exact test), indicating that disease-associated target genes are more likely to be cell-type-specific ( Fig. 2f ).
To gain further insight into pathogenesis of kidney disease, we performed functional annotation of the 27 genes identified by colocalization between kidney-compartment-based eQTLs and CKD GWAS. Using the pathway analysis described in genomescale integrated analysis of gene network (GIANT) 46 , we found that these genes identified as tubule-compartment specific were significantly enriched for a single functional group: endolysosomal function (FDR = 1.5 × 10 −2 ) ( Fig. 2g ). Combining results from both kidney compartments showed enrichment not only for endolysosomal genes, but also related pathways such as autophagy (FDR = 3.59 × 10 −2 ) and the mitochondrial degradation pathway (FDR = 4.58 × 10 −2 ) ( Supplementary Fig. 3c ). These results indicate that the expression of the target genes for kidney function are enriched for a limited number of functional groups. Specifically, we noticed that DAB2 had the greatest number of connections in the functional network and represented a central hub.
Identification of DAB2 as a kidney disease gene.
To leverage our unique eQTL datasets to identify kidney-specific causal genes for kidney disease, we focused on the Complement C9 (C9)-Disabled homolog 2 (DAB2) locus for follow-up functional validation studies. The genotype of rs11959928 (at the DAB2-C9 locus) has been significantly associated with CKD in multiple CKD GWASs 9,10,12 . The DAB2 and C9 genes are located near rs11959928; however, it was unclear which gene is regulated by the disease-causing variant. In eQTL analysis at the whole-kidney level, the rs11959928 genotype was not significantly associated with either DAB2 or C9 levels 30 . Compartment-based eQTL analysis identified an association between the rs11959928 genotype and the DAB2 level, but not the C9 level. Furthermore, this eQTL was only identified in tubule eQTLs, not in glomerulus eQTLs (Fig. 3a, b ). The tubule-specific eQTL effect of rs11959928 on DAB2 can be replicated by a recent kidney cis-eQTLs study 47 ( Supplementary Fig. 4a ). Although DAB2 is broadly expressed in multiple tissues and cell types, rs11959928 was not identified as a significant eQTL in the 44 GTEx tissue samples 25 (Fig. 4a ). Meta-analysis 48 of our kidney compartment and 44 GTEx tissues indicated that rs11959928 showed a tubule-specific eQTL effect only on DAB2 (m = 0.855) and not on C9 (m = 0.407) ( Fig. 4b) .
Using single-cell RNA-seq of mouse kidney tissue samples, we found that in the kidney, Dab2 expression is restricted to the proximal tubules and to macrophages ( Fig. 2a ). Although one prior study reported a significant eQTL effect of rs11959928 for DAB2 in peripheral blood mononuclear cells (PBMCs) 49 , it was in the opposite direction (z-score = -32.69, P = 5.123 × 10 −124 ) ( Supplementary Fig. 4b ), and this eQTL was not replicated in the whole-blood samples of the GTEx dataset (β = 0.032, P = 0.394) ( Supplementary Fig. 4c ).
Given differences in eQTL effects, we examined the functional annotation of this candidate GWAS and eQTL locus in the human kidney and other tissues and cells by comparing the enrichment for histone H3K27ac, a marker that distinguishes an active enhancer from poised ones. We noticed a binding peak of H3K27ac that is specifically found in kidney, but not in macrophages or any other cells analyzed by ENCODE (Fig. 4c ). The kidney-specific enhancer peak coincided with the CKD GWAS region, suggesting that this region might have a functional role in kidney tubule cells and likely explaining the existence of a kidney eQTL effect for a gene with a relatively broad expression profile.
Furthermore, we also noted that GTEx (GTEx v7; https://www. gtexportal.org/) reported a kidney-specific DAB2 isoform when compared to other human tissues. This isoform contains an exon skipping (chr5: 39,382,720-39,383,373, hg19) and was highly expressed in the kidney. Using the LeafCutter 50 method for isoform quantification, we confirmed the presence of this isoform in our human kidney tubule dataset ( Supplementary Fig. 4d ). Kidney-specific isoform expression can also contribute to the specific eQTL effect on DAB2 in tubule cells. In summary, we have identified the CKD associated variant rs11959928 with tubule-specific effects on DAB2 expression levels. Our results indicate a kidney-specific isoform expression and a kidney-specific enhancer peak at this locus that is not present in other cell types and suggest genetic variation at this enhancer could lead to kidney diseases through higher DAB2 expression in renal tubules.
Dab2 alters kidney disease development in mice. To determine whether C9 or Dab2 plays a role in kidney disease development, we performed in vivo validation using animal models with reduced gene dosage. Mice with global knockout of C9 and mice heterozygous for the gene were phenotypically normal, and we did not observe structural or functional changes in the kidney (Fig.  5a-c) . We reasoned that C9 might alter injury response and still be responsible for kidney disease development. Therefore, we subjected wild-type (WT) and C9 +/− mice to folic-acid-induced kidney injury (FAN; folic acid nephropathy) ( Supplementary Fig. 5a ). Transcript levels of kidney fibrosis markers including Fibronectin 1 (Fn1), Collagen 1a1 (Col1a1) and Collagen 3a1 (Col3a1) were significantly higher in WT mice injected with folic acid. However, we found no differences between WT and C9 +/− mice in this CKD model (Fig. 5a ). Similar results were obtained when analyzing histological lesion on PAS-stained and Sirius Red-stained kidney sections (Fig. 5b,c) .
Next, we studied the role of Dab2, as the CKD GWAS variant also influenced the expression of Dab2 in the kidney. We generated mice with tubule-epithelial-specific dose reduction of Dab2 using the well-characterized mice with tubule-specific expression of Cre recombinase under control of the Cdh16 (Ksp) promoter (Ksp-Cre mice) and mice with Dab2 flanked by loxP (Dab2 flox mice) ( Supplementary Fig. 5b) . The genetic and eQTL study integration suggested that the risk allele was associated with higher DAB2 levels in the kidney (Table 1) . We did not observe any renal functional or histological abnormalities in Ksp-Cre and Dab2 flox/+ mice at baseline. Next, we subjected these animals to folic-acid-induced acute and chronic kidney injury. A significantly lower expression of fibrosis markers (Fn1, Col1a1 and Col3a1) at the mRNA level in Ksp-Cre and Dab2 flox/+ mice was observed after folic acid injection (Fig. 5d ). We also found that the degree of disease was significantly lower in tubule-specific Dab2-knockout mice compared with folicacid-treated WT mice (Fig. 5e, f) , indicating that the directionality is consistent with the GWAS effect direction. In addition to the FAN model, we also found a lower level of interstitial fibrosis in mice with tubule-specific loss of Dab2 subjected to unilateral ureter obstruction (UUO) ( Supplementary Fig. 5c-e ). To understand the role of Dab2 in kidney fibrosis development, we generated primary renal tubule epithelial cells (TECs) with lower Dab2 levels by infecting cells from Dab2 flox/+ mice with Cre-eGFP adenovirus ( Supplementary Fig. 6a ). Injured TECs release tumor growth factor (TGF)-β (encoded by Tgfb1), which is one of the best-known profibrotic cytokines 51, 52 . TGF-β levels are known to be higher in the UUO model of fibrosis 53 , and we confirmed the higher Tgfb1 expression in the folic-acid-induced fibrosis mouse model as well ( Supplementary Fig. 6b ).
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We found that lowering the Dab2 level resulted in less TGF-β -induced SMAD2 and SMAD3 phosphorylation of cultured tubule cells (Fig. 5g) . In our experiments, Dab2 had no significant effect on p38 or ERK phosphorylation ( Supplementary Fig. 6c ), but we found lower JNK phosphorylation in absence of Dab2 (Fig. 5h) . As SMAD3 and JNK mediate TGF-β -induced profibrotic gene expression, we found that reducing Dab2 levels resulted in less TGF-β -induced fibronectin and collagen1 production in cultured tubule cells ( Fig. 5h and Supplementary Fig. 6d ).
In summary, these results indicate that Dab2 in tubule cells is a likely causal gene for CKD development, as Dab2 plays an important role in TGF-β -induced profibrotic gene expression.
Discussion
A key limitation to disease understanding is that most human studies cannot go beyond descriptive and correlative analysis, and animal models often show limited relevance to human disease development as genotypes are established before disease development. GWASs provide valuable insight into disease mechanisms. Although GWAS has identified noncoding genetic variants associated with CKD, the underlying genes, cell types and mechanism still remain elusive. Here we generated new datasets and conducted a genome-and transcriptome-wide scan for genetic variants associated with gene expression variation (eQTLs) in two kidney compartments: tubules and glomeruli. Although some cell-type-specific eQTL analyses have been performed in blood samples, we believe that this is the first study to directly characterize cell-type specificity of different compartments on solid organ samples 38 . By integrating this data with prior GWASs, epigenome analysis and single-cell transcriptome analysis, we have identified putative causal genes for 24 of the 83 GWAS loci. To date, GTEx has conducted eQTL analysis on 53 human tissues, 44 of which had sufficient sample size for further analyses (GTEx v6p). Kidney, however, was not included owing to the limited sample size 25 . By comparing our results with GTEx, we showed that the majority of eQTLs are shared between multiple GTEx tissue types as well as two kidney compartments. Strikingly though, we observed that previously identified CKD GWAS loci were more likely to be associated with eQTLs that are compartment-specific, that reside further away from promoters and that possibly act by modulating compartment-specific active enhancers compared to those identified by bulk-sequencing data analysis. Our study highlights that cell-type-specific eQTL and epigenome datasets are crucial components of post-GWAS prioritization and mechanism studies. Deeper insight into these cell-type-specific mechanisms may reveal that many diseases and conditions are perturbations of a specific cell type rather than specific organs. Next, we investigated whether specific regulatory elements were enriched for compartment-specific or compartment-shared eQTLs. Functional annotation analysis indicated that compartment-and tissue-shared eQTLs were more likely to be located in promoter regions. On the other hand, by incorporating single-cell mouse kidney RNA-seq data, we demonstrate that disease-specific target gene regulation is likely to be cell-type specific, and the most likely causal GWAS variants are localized to cell-type-specific enhancers. We then focused on the DAB2 locus to illustrate such cell-type-specific eQTL and enhancer effects.
We used the comprehensive and new compartment-specific RNA-seq dataset and computational analysis as well as rigorous in vitro and in vivo assays to identify DAB2 as a new causal gene for CKD pathophysiology. The rs11959928 variant has been associated with CKD in multiple GWASs [10] [11] [12] . Yet, this variant was not associated with gene expression changes in GTEx 25 or in bulk kidney eQTL datasets 30 . Furthermore, even though DAB2 is expressed across multiple cell types, we observed that this variant only displays tubule-specific effects on DAB2 expression. Single-cell RNAseq data further refined the target tissues to two cell types (tubules and macrophages) with high DAB2 expression in the kidney. Of note, a prior report 49 showed a macrophage-specific eQTL effect of DAB2 of this variant in the opposite direction as compared to the tubule-specific eQTL direction. However, this effect and direction were not replicated in the larger GTEx dataset 25 , and follow-up in vivo results failed to show consistent effects of macrophage-specific Dab2 reduction on kidney fibrosis development (unpublished data). On the basis of the replicated eQTL effect, combination of strong colocalization between the tubule-specific eQTLs and CKD GWAS and the protection from kidney injury observed in Dab2-knockout mice, we conclude that the CKD risk allele at the DAB2 locus from GWAS is associated with higher expressed levels of DAB2 in tubule cells, leading to tubular fibrosis.
DAB2 is a central adaptor protein in several receptor-mediated pathways 54 . In vitro studies have shown that DAB2 is required for TGF-β -mediated signaling in epithelial cells 55 . TGF-β is one of the strongest inducers of kidney fibrosis and CKD 51 . The CKD-riskincreasing allele of the underlying causal variant likely modifies this enhancer function specifically in tubule cells, raising cytokine levels (including TGF-β ), thus altering endocytosis and inducing downstream development of fibrosis through DAB2. We demonstrate the role of tubule-specific DAB2 in kidney disease development using cell-type-specific-knockout mice.
Through gene-gene network analysis, we also show that these 24 putative causal genes are enriched in a specific kidney cell type and highlight the endolysosomal pathway as a likely pathophysiological mechanism in the proximal tubules for kidney disease development. Proximal tubule epithelial cells are the most common cell type in the kidney, and dedifferentiation of these highly specialized cells has been linked to a reduction in kidney function and the development of kidney disease 56, 57 . The proximal tubules play a key role in initial processing of the primary blood filtrate, as the renal glomerulus processes more than 144 L of primary filtrate a day. Further, the proximal tubules have one of the highest levels of endocytic activity in the body to reclaim critical nutrients from the primary filtrate 58 . Alterations in the endocytic, lysosomal and autophagy pathways of these cells have been previously observed in animal models and individuals with kidney disease 59, 60 . Now, our genetic studies can help to refocus attention to this specific cell type and mechanisms in CKD development.
In summary, this is one of the first and most extensive post-GWAS annotations of CKD risk loci. We combined compartment-specific transcriptome, genome, epigenome and single-cell sequencing data to identify new genes, cell types and mechanisms contributing to the CKD pathophysiology. The integration of these datasets provides critically needed information for the field. Our data delivered new biological insight by the identification of DAB2 as kidney-disease-causing gene and the additional 26 putative candidate genes. We also show that renal tubule cells and the endolysosomal pathway play an important role in CKD, providing a new mechanism for disease development.
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Methods
Sample procurement. Human kidney tissue collection was approved by the University of Pennsylvania Institutional Review Board. Kidney samples were obtained from surgical nephrectomies. Nephrectomies were de-identified, and the corresponding clinical information was collected through an honest broker; therefore, no consent was obtained from the subjects.
Collected tissue was immersed in RNAlater (Ambion no. AM7020) solution at 4 °C for several hours before being stored at -80 °C in RNAlater. Tissue was thawed on ice, placed in RNAlater, and manually microdissected for glomerular and tubular compartments. In general, 60-150 glomeruli that readily released from the capsule were collected and placed into RNeasy RNA Tissue Lysis Buffer Solution (per Qiagen RNeasy kit manufacturer instructions (Qiagen no. 74106)). We refer to the remaining compartment as tubule throughout the article.
Part of the tissue core was formalin fixed and paraffin embedded. These samples were later sectioned and stained with H&E or periodic acid schiff. Our local renal pathologist performed an unbiased review of the tissue section by scoring multiple parameters.
DNA was isolated using the Qiagen DNAeasy or MagAttract High Molecular Weight DNA Kit (Qiagen no. 67563), according to the manufacturer's instructions. DNA was quantified by the Invitrogen Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen no. P11496).
Data production. Genomic DNA isolated from whole kidney or tubule tissue was used for genotyping. 424 individuals were genotyped using Affymetrix Axiom Biobank genotyping array. Quality control steps were performed using PLINK 1.9 (ref. 61 ), and ultimately, we excluded 16 samples. First, two samples were excluded because of their SNP data, which were ambiguous regarding sex. An additional four samples were excluded because of their low call-rate (< 5%), and another two samples were excluded because of elevated heterozygosity ( Supplementary Fig. 7a ). To further identify potential sample contamination, identity-by-descent (IBD) was computed between all pairwise sample combinations, and eight samples were excluded due to their high PI_HAT (> 0.2).
To quantify population structure, principal component analysis (PCA) implemented in EIGENSTRAT was conducted on these final 408 samples, with additional genotype data from 395 HapMap2 samples (112 CEU, 84 CHB, 86 JPT, 113 YRI) and 2,504 samples from the 1,000 Genomes Project Phase 1 (release v3, 661 AFR, 347 AMR, 504 EAS, 503 EUR, 489 SAS), respectively 62, 63 . Plots of the two main principal components (PCs) for each dataset are shown in Supplementary  Fig. 7b ,c. Subsequently, genotypes of the 408 samples were phased with SHAPEIT2 (ref. 64 ) and imputed with IMPUTE2 (ref. 65 ), using multiethnic panel reference 66 from 1000 Genomes Phase 1 v3.
Separated by two kidney compartments, RNA was isolated from a total of 329 tubule samples and 311 glomerulus samples from up to 359 individuals. RNA quality was assessed with the Agilent Bioanalyzer 2100. Only samples with RIN scores above 7 and a minimum total RNA of 100 ng were used for cDNA production. Nonstrand-specific, polyA + -selected RNA-seq libraries were generated using the Illumina TruSeq protocol. Libraries were sequenced to a median depth of 35 million 100-bp single-end reads. After first assessing sequence quality using FastQC and then trimming the adaptor and lower-quality bases using Trim-galore, RNA-seq reads were aligned to the human genome (hg19/ GRCh37) using STAR (v2.4.1d) based on GENCODE v19 annotations 29, 67 . Genelevel expression was estimated on uniquely mapped reads as reads per kilobase of transcript per million mapped reads (RPKM) using HTSeq 0.9.1 (ref. 68 ) and DESeq2 (ref. 69 ). Samples with less than 15 million mapped reads were excluded.
For eQTL analysis, only samples with European ancestry and absence of significant kidney structural changes (tubular fibrosis < 10%; glomerular sclerosis < 10%) were used. Variants were excluded from analysis if they: (i) had a call rate < 95%; (ii) had a MAF < 5%; (iii) deviated from Hardy-Weinberg Equilibrium (P < 10 −6 ); and (iv) had an imputation info score < 0.4. Finally, 121 samples were used for tubule eQTL analysis, and 119 samples were used for glomerulus eQTL analysis. In addition, genotype-based PCA analysis was conducted again using the final set of tubule and glomerulus samples, and then the first six PCs were used as covariates ( Supplementary Fig. 7d,e ). We also generated a variant cell format (VCF) file with dosages for alternative allele counts used as input for the Matrix eQTL and FastQTL software packages 70, 71 .
Cis-eQTL mapping. We conducted cis-eQTL (further just referred to as eQTL) mapping with 121 samples of tubules and 119 samples of glomeruli. Only genes having at least 0.1 RPKM in two or more samples were considered significantly expressed and used for eQTL mapping. Within each compartment, quantilenormalization was performed on RPKMs, and then expression measurements for each gene were rank-based inverse normal transformed. To remove the effects of unobserved confounding variables, PEER was performed for 15 factors on gene expression with age, gender, collected site, sequencing batch, RNA integrity number (RIN) and fibrosis percentage (for tubule samples) or sclerosis percentage (for glomerulus samples) as covariates 72 . The Pearson correlation P between known clinical variables and 15 PEER factors calculated by 121 tubule RNA-seq samples are shown in Supplementary Fig. 7f . The Pearson correlation P between known clinical variables and 15 PEER factors calculated by 119 glomerulus RNA-Seq samples are shown in Supplementary Fig. 7g . Finally, once the PEER factors were regressed out, the residuals of the analysis with rank-based inverse normal transformation were used as expression measurements in following eQTL mapping, and 32,596 genes were used for tubule analysis as well as 31,635 for glomeruli analysis.
The cis window was defined as 1 Mb up-and downstream of the transcriptional start site (± 1 Mb), and we tested about 1.25 × 10 8 gene-SNP pairs for each compartment. Nominal P values were calculated for each SNP-gene pair with FastQTL using linear regression with an additive effect model and were adjusted by six genotype PCs. Significance of the top associated variant per gene was estimated by adaptive permutation with the setting '-permute 10000' in FastQTL. Beta distribution-adjusted empirical P values were used to calculate q using Storey's q method 73 , and a q threshold ≤ 0.05 was applied to identify eGenes (eQTL-containing genes).
Next, a genome-wide empirical P threshold, P t , was defined as the empirical P of the gene closest to the 0.05 FDR threshold. P t was used to calculate a nominal P threshold for each gene based on the beta distribution model (from FastQTL) of the minimum P distribution f(P min ) obtained from the permutations for the gene. For each eGene, variants with a nominal P below the gene-level threshold were considered significant as eVariants 25 .
Meta-analysis of multiple-tissue eQTL mapping. The eQTL summary results of 44 other human tissues were downloaded from GTEx (v6p; www.gtexprotal.org) 25 . To evaluate which of the GTEx eQTLs replicated the significant SNP-gene pair eQTLs found in the kidney eQTL study, the π 1 statistic was calculated to estimate the fraction of true positive eQTLs, considering the formula π 1 = 1-π 0 , where π 0 is the estimated fraction of null eQTLs from the full distribution of P. For example, for tubule eQTL, eGenes and their top significant SNPs were selected. The nominal P values of these SNP-gene pairs in another GTEx eQTL were extracted, and then π 1 was calculated on these P values using Storey's q method 73 .
To further define tubule-specific eGenes and glomerulus-specific eGenes, METASOFT, a meta-analysis method, was performed on all variant-gene pairs that were significant (FDR < 5%) in at least one of the 46 tissues (2 kidney compartments and 44 GTEx tissues) based on the single-tissue results from FastQTL. A random effects model in METASOFT (called RE2) was used, and the posterior probability that an eQTL effect exists in a given tissue (called m) was calculated for each SNPgene pair and tissue tested 48 . A significance cutoff of m > 0.9 was used to discover high-confidence eQTLs. On the basis of this meta-analysis result, tubule-specific eGenes (glomerulus-specific eGenes) were defined as having m > 0.9 in less than five tissues, including tubule (glomerulus). In contrast, tubule-shared eGenes (glomerulus-shared eGenes) were defined as having m > 0.9 in more than 40 tissues, including tubule (glomerulus) ( Supplementary Fig. 8a) .
To further test the sensitivity of the original results to these cut-offs, we changed the threshold numbers and re-estimated the enrichment results of tubule-specific eGenes and tubule-shared eGenes. Even though the P values are slightly inflated, we found that chronic kidney disease, glomerular filtration rate and metabolite traits are still the top traits enriched for tubule-specific eGenes, and tubule-shared eGenes are enriched for some common human diseases ( Supplementary Fig. 8b-d) .
To identify tubule-compartment-specific eGenes, glomerulus-compartmentspecific eGenes and kidney-compartment-shared eGenes, meta-tissue, which was used to address effect-size heterogeneity in detection of eQTLs across multiple tissues, was performed on three eQTL datasets 74 , tubule eQTLs, glomerulus eQTLs and our previous whole-kidney eQTLs 30 , to remove the effect brought by collecting multiple tissues from the same individuals.
Functional annotation. Traits and disease-associated genetic variants were extracted from GWAS Catalog v1.0.1 (accessed 4 January 2017; https://www. ebi.ac.uk/gwas/) 41 . These variants were used for enrichment analysis for kidney compartment eQTLs.
Human kidney-specific ChIP-seq data can be found at GEO accession numbers GSM621634, GSM670025, GSM621648, GSM772811, GSM621651, GSM1112806 and GSM621638. Different histone markers were combined into chromatin states using ChromHMM 75, 76 . To quantify kidney eQTL enrichment in these regulatory regions, the top significant SNPs per eGenes were used as tested eQTL subset. To calculate enrichment significance, the data was compared between the tested eQTL subset and a randomly selected SNP set that was matched for MAF (< 0.01) and distance to the TSS of target genes (< 2.5 kb).
Transcription factor ChIP-seq (161 factors) was extracted from ENCODE project TFBS clusters (V3), and the enrichment analysis procedure was as the same as formerly described 29 .
GWAS analysis.
Leading SNPs of CKD GWAS. eGFR-associated GWAS SNPs were collected from the CKDGen Consortium and several other studies to determine whether kidney disease traits in our eQTLs were enriched 9-12 . This step yielded 83 leading SNPs.
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